Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Salivary Gland Neoplasms × pazopanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 60 Sarcoma 38 Neoplasms 20 Neoplasm Metastasis 20 Breast Neoplasms 17 Ovarian Neoplasms 15 Carcinoma, Non-Small-Cell Lung 13 Melanoma 6 Leiomyosarcoma 6 Kidney Neoplasms 6 Hemangiosarcoma 6 Thyroid Neoplasms 5 Recurrence 5 Lung Neoplasms 5 Liposarcoma 5 Glioblastoma 5 Fallopian Tube Neoplasms 5 Urinary Bladder Neoplasms 4 Prostatic Neoplasms 4 Pancreatic Neoplasms 4 Osteosarcoma 4 Neurofibrosarcoma 4 Clear-cell metastatic renal cell carcinoma 4 Chondrosarcoma, Extraskeletal Myxoid 4 Uterine Cervical Neoplasms 3 Solid Tumors 3 Sarcoma, Synovial 3 Sarcoma, Alveolar Soft Part 3 Neuroendocrine Tumors 3 Histiocytoma, Malignant Fibrous 3

Interventions

Docetaxel 16 Cisplatin 15 Carboplatin 12 Radiotherapy 9 Magnetic Resonance Spectroscopy 9 Cetuximab 9 Biopsy 9 pembrolizumab 8 Paclitaxel 8 Immunohistochemistry 8 Erlotinib Hydrochloride 8 Trastuzumab 7 Radiotherapy, Intensity-Modulated 7 Chemotherapy, Adjuvant 7 Specimen Handling 6 Gemcitabine 6 Radiotherapy, Conformal 5 Vorinostat 4 Taxes 4 Radiosurgery 4 Gene Expression Profiling 4 Fluorodeoxyglucose F18 4 Capecitabine 4 Bevacizumab 4 trastuzumab deruxtecan 3 darolutamide 3 Surgical Procedures, Operative 3 Sorafenib 3 Radiation 3 Polymerase Chain Reaction 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02393820 2019-10-29

PACSA-ORL02

UNICANCER

Phase 2 Completed

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡